Neuroendocrine tumors are generally slow growing and are frequently discovered when metastatic spread has occurred. This leaves room for multiple treatments, individualized through a multidisciplinary approach that considers tumor type, extension, and related symptoms. In almost 15 years of academic phase II trials, PRRT with either 90Y-octreotide or 177Lu-octreotate proved to be efficient, with tumor responses in more than 30% of patients, symptom relief and QoL improvement, biomarker reduction, and, ultimately, an impact on survival.

Peptide Receptor Radionuclide Therapy (PRRT): clinical Application

PAGANELLI, Giovanni
2015

Abstract

Neuroendocrine tumors are generally slow growing and are frequently discovered when metastatic spread has occurred. This leaves room for multiple treatments, individualized through a multidisciplinary approach that considers tumor type, extension, and related symptoms. In almost 15 years of academic phase II trials, PRRT with either 90Y-octreotide or 177Lu-octreotate proved to be efficient, with tumor responses in more than 30% of patients, symptom relief and QoL improvement, biomarker reduction, and, ultimately, an impact on survival.
978-111903165-9
978-111852153-3
177Lu-DOTATATE; 90Y-DOTATOC; Neuroendocrine tumor; PRRT; Biochemistry, Genetics and Molecular Biology (all); Chemistry (all); Medicine (all)
File in questo prodotto:
File Dimensione Formato  
bodei2015.pdf

solo gestori archivio

Tipologia: Pre-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 169.23 kB
Formato Adobe PDF
169.23 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11392/2374509
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact